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Aortic Valve Implantation
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Sébastien Bergeron, MD,* Mélanie Côté, MSC,* Olivier F. Bertrand, MD, PHD,*
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Quebec City, Quebec, Canada
O B J E C T I V E S The aim of this study was to: 1) determine the usefulness of transesophageal
echocardiography (TEE) as the primary technique to guide transapical (TA) transcatheter aortic valve
implantation (TAVI); and 2) to compare TEE with angiography as the primary imaging modality for
TA-TAVI guidance.
B A C KG ROUND TEE has been routinely used as an adjunct to angiography during TA-TAVI
procedures, but very few data exist on the use of TEE as the primary imaging technique guiding TA-TAVI.
METHOD S One hundred consecutive high-risk patients (mean age 79  9 years, mean logistic
EuroSCORE: 25.8  17.6%) who underwent TA-TAVI in our center were included. The Edwards valve was
used in all cases, and all procedures were performed in an operating room without hybrid facilities. The
TA-TAVI was primarily guided by angiography in the ﬁrst 25 patients (A-TAVI group) and by TEE in the
last 75 patients (TEE-TAVI group). Procedural, 30-day, and follow-up results were evaluated.
R E S U L T S No differences were observed between groups at baseline except for a higher (p 0.001)
prevalence of moderate or severe mitral regurgitation in the TEE-TAVI group. The procedure was
successful in 97.3% and 100% of the patients in the TEE-TAVI and A-TAVI groups, respectively (p  1.0),
and a lower contrast volume was used in the TEE-TAVI group (12 [5 to 20] ml vs. 40 [20 to 50] ml, p 
0.0001). There were no differences between groups in the occurrence of valve malposition needing a
second valve (TEE-TAVI: 5.3%; A-TAVI: 4%; p  1.0) or valve embolization (TEE-TAVI: 1.3%; A-TAVI: 4%;
p  0.44). The results regarding post-procedural valve hemodynamic status and aortic regurgitation
were similar between groups. The survival rates at 30-day and 1-year follow-up were 87% and 75% in
the TEE-group and 88% and 84% in the A-TAVI group, respectively (log-rank  0.49).
CONC L U S I O N S TEE-TAVI was associated with similar acute and midterm results as A-TAVI and
signiﬁcantly reduced contrast media use during the procedures. These results suggest the feasibility and
safety of performing TA-TAVI procedures in an operating room without hybrid facilities, but larger
studies are needed to conﬁrm these ﬁndings. (J Am Coll Cardiol Img 2011;4:115–24) © 2011 by the
American College of Cardiology Foundation
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ransapical transcatheter aortic valve implan-
tation (TA-TAVI) has emerged as an alter-
native treatment for those high-risk patients
with severe symptomatic aortic stenosis (AS)
n which the presence of small and/or diseased
liofemoral arteries precludes the use of a transcath-
ter transfemoral approach (1–7). Angiography has
een the primary imaging technique for guiding
AVI, and several angiographic injections are often
See page 125
required to obtain the best view of the native aortic
valve and to position the transcatheter valve (8).
However, difficulties in obtaining an optimal view of
the native valve and the absence of a reference for the
ventricular end of the valve prosthesis might be a
limitation for the angiographic guidance of
valve positioning and deployment. Also, sev-
eral centers have performed TA-TAVI pro-
cedures in an operating room with a fluoro-
scopic C-arm (7,9–12), which in turn
increases the difficulties in obtaining optimal
angiographic images. Also, the risk of con-
trast nephropathy is potentially very high in
patients undergoing TAVI, who are usually
very old and exhibit a high prevalence of
chronic kidney disease (CKD) (1–6,13).
Transesophageal echocardiography
(TEE) has been used as a complementary
imaging tool during TAVI procedures
(14,15). The TEE images depict the aor-
tic and ventricular ends of the transcathe-
ter valve and provide a ventricular refer-
ence (anterior leaflet of the mitral valve)
that might facilitate valve positioning.
Also, the use of TEE rather than angiography
during valve prosthesis positioning would reduce
the use of contrast media, and this might lead to a
decrease in the occurrence of acute kidney injury
(AKI) and the need for hemodialysis after the
procedure. However, few data exist on the use of
TEE as a primary imaging modality to guide TAVI
procedures (16,17). The aims of this study were to:
1) determine the usefulness of TEE as the primary
technique for guiding TA-TAVI; and 2) compare
TEE with angiography as primary imaging tech-
niques for TA-TAVI guidance.
M E T H O D S
Patients. A total of 100 consecutive patients diag-
ing
rtic
se
l
rticosed with symptomatic severe AS who underwent tA-TAVI in our center between May 2007 and
une 2010 under the compassionate clinical use
rogram approved by the Canadian Department of
ealth and Welfare (Ottawa, Canada) were in-
luded in the study. TAVI was approved for pa-
ients with symptomatic severe AS considered ei-
her nonoperable or very high-risk surgical
andidates, and all patients provided signed in-
ormed consent for the procedures. TA-TAVI was
erformed in the operating room by a team of
ardiac surgeons, interventional cardiologists, and
nesthesiologists with techniques extensively de-
cribed in previous reports (3). The 23- or 26-mm
dwards SAPIEN or SAPIEN-XT transcatheter
eart valves (Edwards Lifesciences, Inc., Irvine,
alifornia) were used in all cases. All clinical,
chocardiographic, procedural, and post-
rocedural data were prospectively collected. Pro-
edural success was defined as the implantation of
functioning valve within the aortic annulus,
ithout intraprocedural mortality. All major pro-
edural and post-procedural (30-day) complica-
ions were recorded, and all patients underwent a
ransthoracic Doppler echocardiography at hos-
ital discharge.
Primary imaging technique: angiography. The first
5 patients of this series underwent TA-TAVI with
ngiography as the primary imaging technique (A-
AVI group). The procedures were performed in
n operating room with a fluoroscopic C-arm. At
east 2 orthogonal angiographies were performed at
he beginning of the procedure. The view in which
he 3 aortic sinuses and aortic valve leaflets were
hown on approximately the same plane was used
or valve positioning and deployment. All angiog-
aphies were performed with a pump injection of 10
o 20 cc of mixed solute (1:1) of nonionic contrast
edia (iodixanol) and saline. After balloon valvu-
oplasty, the valve prosthesis was advanced, and
everal angiographies were performed during valve
rosthesis positioning to further determine the
osition of the crimped valve and its relationship on
perpendicular plane with the aortic cusps. The
ptimal positioning of the valve prosthesis before
eployment was established when approximately
ne-half of the stent containing the valve prosthesis
as above/below the aortic annulus as determined
y angiography (Fig. 1). Valve deployment was
erformed under rapid pacing to minimize the risk
f valve embolization. A final aortography after
alve deployment was performed to confirm the
orrect position of the prosthesis and to determineA B B R E V I A T I O N S
A N D A C R O N YM S
AKI acute kidney injury
AR aortic regurgitation
AS aortic stenosis
A-TAVI angiography guid
transapical transcatheter ao
valve implantation
CKD chronic kidney disea
TA-TAVI transapical
transcatheter aortic valve
implantation
TEE transesophageal
echocardiography
TEE-TAVI transesophagea
echocardiography guiding
transapical transcatheter aohe presence and degree of aortic regurgitation
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117(AR). TEE was also used in all the procedures as a
complementary imaging tool, but all decisions re-
garding the final positioning and deployment of the
valve prosthesis were based primarily on the angio-
graphic images.
Primary imaging technique: TEE. The last 75 consec-
utive patients of this series underwent TA-TAVI
guided by TEE as the primary imaging technique
(TEE-TAVI group) and with fluoroscopy/
angiography as a complementary imaging tool. All
procedures were performed in an operating room
with a C-arm fluoroscopy system similar to the one
used in the A-TAVI group. A pigtail catheter was
positioned in the aortic root just at the level of the
aortic annulus as a landmark, but no angiographic
images were obtained at the beginning of the
procedure. After balloon valvuloplasty, the valve
prosthesis was advanced toward the native aortic
valve, and special care was taken to appropriately
identify the aortic and ventricular ends of the stent
containing the valve by TEE as well as the hinge
point of the anterior mitral leaflet as the principal
anatomic marker for positioning the ventricular end
of the stent (Fig. 2, Online Videos 1 and 2). The
ong-axis (approximately 120° to 130°) TEE view
as used to visualize the prosthetic valve. Achieving
perpendicular position of the valve prosthesis with
espect to the aortic annulus as well as an optimal
oaxiality with respect to the long axis of the
scending aorta was important to obtain an optimal
iew of the valve prosthesis, and this was accom-
lished by manipulating (pulling/pushing) the
uidewire through which the valve prosthesis was
dvanced (Fig. 3). Once an optimal TEE view of
he valve prosthesis was obtained, the optimal
ositioning of the valve was achieved by aligning
he ventricular end of the valve prosthesis with the
inge point of the anterior leaflet of the mitral valve
Fig. 2). The final adjustment of valve positioning
nd valve deployment was performed under rapid
acing (Online Videos 3 and 4). After valve deploy-
ent, TEE imaging evaluated the correct position
f the prosthesis as well as the presence, degree, and
ype (central, paravalvular) of AR. Fluoroscopy was
lso used in all procedures as a complementary
maging tool. One to 2 angiographic injections (10
o 20 cc of iodixanol-saline, 1:1) were used in 57 of
he 75 patients either during valve positioning or
fter valve implantation, but all decisions with
egard to both the final positioning and deployment
f the valve prosthesis and the need for further
ntervention (post-balloon dilation, implantation ofsecond valve prosthesis) after valve implantationere primarily based on TEE images. In 18 pa-
ients no angiography was performed (TEE-
uoroscopy guidance alone) due to very severe
KD (n  8), severe peripheral vascular disease
recluding the femoral access (n  5), presence of
omplex plaques in the aortic arch (n  2), and
edical team decision with no specific reason de-
ailed (n  3).
Follow-up. Clinical follow-up was carried out by
clinical visits or through telephone contact. Patients
were followed at 1 month, 6 months, and 1 year
after the procedure and annually thereafter. Death
and reintervention at any time during the follow-up
period were recorded.
Statistical analyses. Qualitative variables were ex-
ressed as percentages, and quantitative variables
ere expressed as mean  SD or median (25th to
5th interquartile range) depending on variable
ormality distribution as determined by Shapiro-
ilk tests. Group comparisons were analyzed with
tudent t test or the Wilcoxon rank-sum test for
continuous variables and chi-square test or Fisher
exact test for categorical variables. Analysis of vari-
ance for repeated measures was performed to test
for equal means between baseline and follow-up.
For aortic valve area and mean gradient, a 2-way
analysis of variance for repeated measures with
interaction was used to compare the changes in
aortic valve area and mean gradient between base-
Figure 1. Valve Positioning Under Angiography Guidance
White arrows highlight “half-half” of the stent in a perpendicu-
lar plane of the aortic annulus. Yellow arrows highlight the pig-
tail catheter just at the level of the right sinus of Valsalva. The
red arrow highlights the distance between the crimped valve
and the left main coronary artery.line and follow-up and between TEE-TAVI and
2thesis perpendicular to
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118TA-TAVI groups. Survival rates at 1-year
follow-up were presented as Kaplan-Meier curves,
and the log-rank test was used for comparison
between groups. Differences were considered statis-
tically significant when a p value was 0.05. The
Figure 2. Valve Positioning Under Transesophageal Echocardiog
(A) Transcatheter valve in the left ventricular cavity showing the ve
arrows); the thick yellow arrow highlights the hinge point of the a
(B) Adequate positioning of the valve with the hinge point of the a
tricular end of the valve (thin white arrows). (C) A “too high” (aort
the valve (Online Videos 1, 2, 3, and 4).
oning: Importance of Valve Coaxiality
g of the valve prosthesis. (B) Coaxial position of the valve pros-
the aortic annulus after gentle traction of the guidewire.data were analyzed with SAS statistical software
version 9.1.3 (SAS Institute Inc., Cary, North
Carolina).
R E S U L T S
Baseline clinical and echocardiographic characteris-
tics of the study population are shown in Table 1,
and procedural and 30-day outcomes for the entire
population are shown in Table 2. The procedure
was successful in 98% of the patients, and there
were no procedural deaths. A total of 13 patients
died within the 30 days after the procedure due to
multi-organ failure (n 5), cardiogenic shock (n
), sudden unexplained death (n  2), sepsis (n 
2), cardiac rupture (n  1), and respiratory distress
syndrome (n  1).
Primary imagingmodality for guiding TA-TAVI: angiog-
raphy versus TEE. Baseline clinical and echocardio-
graphic characteristics of the A-TAVI and TEE-
TAVI groups are shown in Table 3. There were no
significant differences between groups at baseline,
hy Guidance
ular and aortic ends of the stent containing the valve (white thin
ior mitral leaﬂet, and the green line highlights the aortic annulus.
ior mitral leaﬂet (thick yellow arrow) as a landmark for the ven-
ositioning of the valve. (D) A “too low” (ventricular) positioning ofrap
ntric
nter
nter
ic) pFigure 3. Valve Positi
(A) Eccentric positioninexcept for a higher prevalence of moderate or severe

0
t
4
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v
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119mitral regurgitation in the TEE-TAVI group. Pro-
cedural and 30-day outcomes grouped according to
the primary imaging modality for guiding the
TAVI procedure are shown in Table 4. There were
no differences between groups with regard to pro-
cedural success (A-TAVI: 100%, TEE-TAVI:
97.3%, p 1.0), but procedural time was shorter (p
0.005) and contrast amount was lower (p 
.0001) in the TEE-TAVI group. Valve emboliza-
ion occurred in 1 patient in each group (A-TAVI:
%; TEE-TAVI: 1.3%, p  0.44). One patient in
he A-TAVI group complicated with severe trans-
alvular AR due to the low positioning of the valve
Table 1. Baseline Characteristics of the Study Population
Baseline Characteristics n  100
Clinical variables
Age (yrs) 79 9
Male sex 41 (41)
Body mass index (kg/m2) 26 5
Diabetes 31 (31)
Dyslipidemia 85 (85)
Hypertension 94 (94)
Current smoking 5 (5)
Congestive heart failure 66 (66)
New York Heart Association functional class
I–II 4 (4)
III–IV 96 (96)
Chronic atrial ﬁbrillation/ﬂutter 20 (20)
Coronary artery disease 68 (68)
Prior coronary artery bypass grafting 41 (41)
Prior valvular surgery 3 (3)
Cerebrovascular disease 31 (31)
Peripheral vascular disease 49 (49)
Chronic obstructive pulmonary disease 39 (39)
Porcelain aorta 23 (23)
Frailty 12 (12)
Creatinine (mg/dl) 1.40 0.80
Estimated glomerular ﬁltration rate (ml/
min/1.73 m2)
52.2 24.0
Estimated glomerular ﬁltration rate 60
ml/min/1.73 m2
65 (65)
Hemoglobin (g/dl) 11.7 1.6
Logistic EuroSCORE (%) 25.8 17.6
Society of Thoracic Surgeons score (%) 8.5 6.0
Echocardiography
Left ventricular ejection fraction (%) 52 14
Left ventricular ejection fraction 40% 19 (23)
Mean gradient (mm Hg) 40 16
Aortic valve area (cm2) 0.62 0.16
Pulmonary artery systolic pressure (mm Hg) 45 14
Moderate/severe mitral regurgitation 28 (28)
Values are expressed as n (%) or mean  SD, unless otherwise noted.
EuroSCORE  European System for Cardiac Operative Risk Evaluation.rosthesis that was treated with the implantation ofa second valve (valve-in-valve procedure). However,
the 2 valves embolized into the left ventricle 48 h
after the procedure. The patient underwent emer-
gent open heart surgery but died within the next
24 h due to severe multiorgan failure. Valve pros-
thesis embolization immediately after valve deploy-
ment occurred in 1 patient in the TEE-TAVI
group, due to the presence of severe septal myocar-
dial hypertrophy protruding into the left ventricular
outflow tract. The prosthesis embolized in the
ascending aorta and was finally deployed in the
distal part of the aortic arch. The patient underwent
successful surgical aortic valve replacement 2
months after the procedure. Valve malposition
needing a second valve due to transvalvular or
paravalvular severe AR occurred in 1 patient (4%) in
the A-TAVI group (low positioning) and in 4
patients (5.3%) in the TEE-TAVI group (low and
high positioning in 1 and 3 cases, respectively).
Two patients in the TEE-TAVI group (2.7%)
complicated with coronary obstruction due to the
displacement of a bulky calcified native aortic leaflet
toward the coronary ostia. One patient was treated
with emergent fem-fem extracorporeal circulation
and coronary bypass graft due to left main coronary
ostia occlusion, and the other patient underwent
transradial coronary angioplasty at 24-h after TA-
TAVI. No cases of valve embolization, valve mal-
position, or coronary obstruction occurred in the
group of 18 patients who underwent TA-TAVI
procedure fully guided by TEE and fluoroscopy,
Table 2. Procedural and 30-Day Outcomes
Periprocedural Variables n  100
Time of procedure “skin to skin” (min) 77 24
Contrast amount (cm3, median 25th–75th IQR) 12.5 (7.0–22.5)
Successful procedure 98 (98)
Procedural death 0
Valve embolization 2 (2)
Valve malposition needing a second valve 5 (5)
Conversion to open heart surgery 3 (3)
Need for hemodynamic support 6 (6)
Coronary obstruction 2 (2)
Life-threatening arrhythmias 7 (7)
30-day outcomes
Myocardial infarction 2 (2)
Stroke 3 (3)
Sepsis 4 (4)
Need for hemodialysis 1 (1)
Permanent pacemaker 5 (5)
Death 13 (13)
Values are expressed as n (%) or mean  SD, unless otherwise noted.
IQR  interquartile range.
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120with no angiography. The procedural time in this
group was 67.4  14.7 min, which was similar to
hat observed in the rest of the TEE-TAVI group
p  0.31) and shorter (p  0.002) compared with
the A-TAVI group. A total of 6 patients (6%)
needed hemodynamic support with cardiopulmo-
nary bypass—1 patient in the A-TAVI group (4%)
and 5 patients in the TEE-TAVI group (6.7%), p
 1.0. The reasons for needing hemodynamic
racteristics, According to Primary Imaging Technique for
cteristics
Primary Imaging Guidance
Angiography
(n  25)
TEE
(n  75) p Value
81 10 78 8 0.13
18 (72.0) 41 (54.7) 0.16
7 (28.0) 24 (32.0) 0.81
20 (80.0) 65 (86.7) 0.52
24 (96.0) 70 (93.3) 1.00
1 (4.0) 4 (5.3) 0.68
lure 16 (64.0) 50 (66.7) 0.81
ociation
0 4 (5.3) 0.46
25 (100.0) 71 (94.7)
tion/atrial ﬂutter 3 (12.0) 17 (22.7) 0.39
ase 15 (60.0) 53 (70.7) 0.33
bypass grafting 8 (32.0) 33 (44.0) 0.35
y 1 (4.0) 2 (2.7) 1.00
ase 10 (40.0) 21 (28.0) 0.32
isease 11 (44.0) 37 (49.3) 1.00
pulmonary 11 (44.0) 28 (37.3) 0.64
1.25 0.62 1.45 0.86 0.28
r ﬁltration rate
2)
57.9 23.9 50.3 23.9 0.17
r ﬁltration rate
73 m2
13 (52.0) 52 (69.3) 0.15
11.6 1.3 11.7 1.7 0.82
26.7 17.9 25.5 17.6 0.78
urgeons score 8.0 3.3 8.7 6.7 0.51
tion fraction (%) 53 16 52 14 0.69
tion fraction 5 (20.0) 14 (18.7) 1.00
Hg) 39 13 41 17 0.56
2) 0.61 0.12 0.62 0.17 0.80
stolic pressure 46 11 44 15 0.66
tral 2 (8.0) 26 (34.6) 0.001
(%) or mean  SD, unless otherwise noted.
System for Cardiac Operative Risk Evaluation; TA-TAVI  transapical transcath-
ion; TEE  transesophageal echocardiography.support during the TA-TAVI procedure were se-vere, maintained hypotension or hemodynamic col-
lapse secondary to ventricular apical tear/bleeding
(n  1), life-threatening arrhythmias (n  2), left
main occlusion (n  1), and severe valvular/
aravalvular regurgitation (n  2). One patient in
he TEE-TAVI group needed surgical aortic valve
eplacement 3 days after the procedure due to se-
ere transvalvular AR leading to cardiac failure.
he 30-day mortality rate was similar between the
-TAVI (12%) and TEE-TAVI (13.3%) groups,
 1.0.
Valve hemodynamic status. There was a significant
reduction in mean aortic gradient (from 40  16
m Hg to 11  6 mm Hg, p  0.0001) and
ncrease in aortic valve area (from 0.62  0.16 cm2
to 1.56  0.29 cm2, p  0.0001) after the proce-
dure, with no differences between TEE-TAVI and
A-TAVI groups (p  0.36 for gradient, p  0.16
or valve area) (Fig. 4). Most patients (65%) had
ome degree of residual AR at hospital discharge,
ostly trivial (53%) or mild (13%). There were no
atients with moderate or severe AR, and there
ere no differences (p  0.69) in the occurrence
nd degree of AR between A-TAVI and TEE-
AVI groups (Fig. 5).
Follow-up. Clinical follow-up was available in all
patients at a median of 6 months (25th to 75th
interquartile range 1 to 18 months) after TA-
TAVI. A total of 8 patients died during the
follow-up period, leading to a cumulative death rate
of 21%. The reasons of death during the follow-up
period were the following: sudden death (n  2);
ung cancer (n  2); larynx cancer (n  1); sepsis
secondary to diabetic foot (n 1); pneumonia (n
1); and end stage renal disease (n  1). There were
no cases of valve structural failure or reintervention.
The Kaplan-Meier survival curves at 1-year
follow-up for the A-TAVI and TEE-TAVI groups
are shown in Fig. 6. Survival rate at 1-year
follow-up was 84% in the A-TAVI group and 75%
in the TEE-TAVI group (log-rank  0.49).
D I S C U S S I O N
In patients diagnosed with severe symptomatic AS
deemed inoperable or at very high surgical risk,
TA-TAVI guided by TEE as the primary imaging
modality was associated with acceptable acute and
midterm results, similar to those obtained with
angiography as the primary imaging technique.
TEE-TAVI was also associated with a significant
decrease in procedural contrast volume withoutTable 3. Baseline Cha
TA-TAVI Guidance
Baseline Chara
Clinical variables
Age (yrs)
Male sex
Diabetes
Dyslipidemia
Hypertension
Current smoking
Congestive heart fai
New York Heart Ass
functional class
I–II
III–IV
Chronic atrial ﬁbrilla
Coronary artery dise
Prior coronary artery
Prior valvular surger
Cerebrovascular dise
Peripheral vascular d
Chronic obstructive
disease
Creatinine (mg/dl)
Estimated glomerula
(ml/min/1.73 m
Estimated glomerula
60 ml/min/1.
Hemoglobin (g/dl)
Logistic EuroSCORE
Society of Thoracic S
Echocardiography
Left ventricular ejec
Left ventricular ejec
40%
Mean gradient (mm
Aortic valve area (cm
Pulmonary artery sy
(mm Hg)
Moderate/severe mi
regurgitation
Values are expressed as n
EuroSCORE  Europeanincreasing the rates of valve embolization or
Abbreviations as in Table 3.
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121malpositioning. Also, the present study suggests
that performing TEE-TAVI procedures in a
regular operating room with a standard fluoro-
scopic C-arm and without hybrid facilities is
feasible and safe.
Angiography and TEE as primary imaging modal-
ity. Aortic angiography has been used as the pri-
mary imaging technique for guiding TA-TAVI
procedures (9–12). This involves the realization of
at least 2 orthogonal angiographic projections to
obtain a view where the 3 aortic leaflets are visual-
ized on approximately the same plane. Obtaining
such a view is 1 critical aspect of the TA-TAVI
procedure guided by angiography and in many cases
might require several angiographies. Also, the final
positioning of the transcatheter valve with approx-
imately one-half of the stent containing the valve
above/below the aortic annulus might be challeng-
ing in some cases and is associated with a somewhat
subjective decision of the physician performing the
procedure, who would have to trace an imaginary
line identifying the aortic annulus and determine
that approximately one-half of the valve prosthesis
would have to be above/below that line. Therefore,
it is not surprising that the final positioning of the
valve prosthesis might in some cases require several
angiographic injections and could be frequently
associated with some discrepancies among the dif-
ferent operators participating in the procedure. All
these potential difficulties associated with the an-
giographic guidance of TA-TAVI might be exac-
erbated by the use of nonoptimal angiographic
view systems such as a fluoroscopic C-arm. The
recent development of the C-THV software
(Paieon, Park Afek, Israel) (18) and real-time
3-dimensional reconstruction systems of the aortic
root and ascending aorta (19,20) should represent
an important step in facilitating and improving the
valve positioning process during TA-TAVI. How-
ever, this implies the use of high-quality imaging
equipment in operating rooms with hybrid facilities,
not yet available in most centers performing TA-
TAVI procedures worldwide. Also, the financial
implications of acquiring such hybrid operating
rooms might slow its implementation in the near
future. In fact, many centers have already decided to
perform TA-TAVI in the catheterization labora-
tory to optimize angiographic imaging during the
procedures. However, many catheterization lab-
oratories do not comply with the strict sterility
regulations of an operating room, and this could
increase the risk of surgical infections. Also,
performing a mini-thoracotomy procedure such0
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Figure 4. Valve Hemodynamic Status After Transapical TAVI
Mean transvalvular gradient and aortic valve area pre- and post-transcatheter aortic
valve implantation (TAVI) in the A-TAVI (A) and TEE-TAVI (B) groups. A-TAVI  angiogra-
phy guiding transcatheter transapical aortic valve implantation; TEE-TAVI  transesopha-Table 4. Procedural and 30-Day Outcomes According to Primary Imaging Technique
for TA-TAVI Guidance
Primary Imaging
Guidance
Angiography
(n  25)
TEE
(n  75) p Value
Periprocedural variables
Time of procedure “skin to skin” (min) 91 29 72 20 0.005
Contrast amount (cm3, median 25-75th IQR) 40 (20-50) 12 (5-20) 0.0001
Rapid pacing runs 5.7 1.9 6.5 1.8 0.06
Successful procedure 25 (100) 73 (97.3) 1.00
Procedural death 0 0 1.00
Valve embolization 1 (4.0) 1 (1.3) 0.44
Valve malposition needing a second valve 1 (4.0) 4 (5.3) 1.00
Conversion to open heart surgery 1 (4.0) 2 (2.7) 1.00
Need for hemodynamic support 1 (4.0) 5 (6.7) 1.00
Coronary obstruction 0 2 (2.7) 1.00
Life-threatening arrhythmias 1 (4.0) 6 (8.0) 0.68
30-day outcomes
Myocardial infarction 1 (4.0) 1 (1.3) 0.44
Stroke 1 (4.0) 2 (2.7) 1.00
Sepsis 0 4 (5.3) 0.57
Need for hemodialysis 0 1 (1.3) 1.00
Permanent pacemaker 0 5 (6.7) 0.33
Death 3 (12.0) 10 (13.3) 1.00
Values are expressed as n (%) or mean  SD unless noted.geal echocardiography guiding transcatheter transapical aortic valve implantation.
moderate,
Abbreviations as in Fig
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122as TA-TAVI in the catheterization laboratory
might be associated with more logistic and tech-
nical difficulties and can also be a challenging
scenario in case of procedural complications re-
quiring emergent conversion to open heart sur-
gery, which occurs in approximately 4% (0% to
7.5%) of TA-TAVI cases (1–7,9 –12).
TEE has been increasingly used in recent years
for guiding cardiac surgical and catheter-based in-
terventions (15). Also, TEE has been used as a
complementary imaging technique from the early
ortic Regurgitation After Transapical TAVI
nd degree of aortic regurgitation after TAVI in the A-TAVI and
roups at hospital discharge. 0: none, 1: trivial, 2: mild, 3:
4: severe. Abbreviations as in Figure 4.
rves After TAVI
urves at 1-year follow-up in the A-TAVI and TEE-TAVI groups.
ure 4.days of TAVI (14,15). TEE enables the accurate
measurement of the aortic annulus, the early detec-
tion of the most important complications associated
with the procedure, and the evaluation of valve
hemodynamic status and the presence and type of
AR (transvalvular vs. paravalvular) immediately af-
ter valve implantation. However, very little data
exist on the role of TEE during key points of the
TAVI procedure, such as valve positioning and
deployment (14–17). As shown in the present
study, TEE can provide very accurate images of the
transcatheter valve before deployment (Fig. 2).
Also, and unlike angiographic guiding, TEE allows
the use of other anatomic markers such as the mitral
valve, which might make TEE a more reliable and
reproducible technique for valve positioning. The
anterior mitral leaflet is separated from the septum
by the subaortic vestibule, which has a fibrous
continuity with a triangle formed between the
noncoronary and left coronary aortic leaflet, making
the aortic and mitral valves directly adjacent to each
other and forming the roof of the left ventricle (21).
We previously reported that the hinge point of the
anterior mitral valve leaflet could be used to guide
the positioning of a transcatheter aortic valve (16).
The present study, which includes the largest con-
secutive series of TA-TAVI procedures primarily
guided by TEE, supports the usefulness of this
anatomical marker for guiding valve positioning
and deployment. The procedure was successful in
97.3% of the cases, with rates of valve embolization,
valve malpositioning needing a second valve, and
conversion to open heart surgery of 1.3%, 5.3%, and
2.7%, respectively—which are similar to the rates
reported in previous TA-TAVI series (4–7,9–12).
Also, the rate of major complications (16%) and
mortality (13.3%) at 30 days were similar to previ-
ous TA-TAVI studies. Ferrari et al. (17) recently
reported the results of 30 patients who underwent
TA-TAVI guided by TEE, with no contrast injec-
tion in up to 22 patients. Interestingly, the echo-
cardiographic landmark used for valve positioning
was, unlike ours, an imaginary line linking the
hinge points of the aortic valve leaflets, with ap-
proximately one-third of the valve prosthesis above
and two-thirds below this line. Consistent with our
results, procedural success was achieved in 96.7% of
the cases, with an incidence of valve embolization of
3.3% and no cases of valve malpositioning. How-
ever, future studies will have to determine the
cost-effectiveness of TEE-TAVI (vs. A-TAVI) as
well as the potential risks associated with radiationFigure 5. A
Incidence a
TEE-TAVI gFigure 6. Survival Cu
Kaplan-Meier survival cexposure for the TEE operators.
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123Avoiding contrast media: a close eye on kidney func-
tion. Patients undergoing TAVI nowadays are
commonly very old and have a high prevalence of
CKD (1–6,13). It is well-known that the use of
contrast media can complicate with the occurrence
of AKI (contrast-induced nephropathy), especially
in those patients with previous CKD, and this
complication has been associated with a significant
increase in post-procedural mortality (22). Also, we
have previously shown that the occurrence of AKI
after TAVI was associated with a 4-fold increase of
in-hospital mortality after the procedure (13). Pre-
vious TA-TAVI studies have reported rates of up to
7% to 13.4% of new hemodialysis after the proce-
dure (6,7,23). The present study showed that the
use of TEE as the primary imaging technique
guiding TA-TAVI procedures was associated with
a dramatic reduction in contrast media use, with a
median contrast volume as low as 12 ml and no
contrast use in up to 18 patients. Interestingly, only
1.3% of the patients required hemodialysis after the
procedure. The absence of differences with the
A-TAVI group in the present study might be due
to both the relatively low amount of contrast (me-
dian 40 ml) used in the A-TAVI group and the
tendency toward a higher degree of renal dysfunc-
tion in the TEE-TAVI group at baseline. Consis-
tent with our results, Ferrari et al. (17) reported no
cases of new hemodialysis among 30 patients who
underwent TA-TAVI guided by TEE. Future
studies will have to evaluate the potential benefits
for post-procedural kidney function of reducing the
contrast volume by guiding the TA-TAVI proce-
dures primarily with TEE.
Study limitations. Our results apply exclusively to
AVI procedures performed by TA approach and
annot be extrapolated to transfemoral procedures.
n our experience valve identification and position-
ng by TEE might be more challenging in those
rocedures performed by transfemoral approach
difficulties in obtaining a perfect coaxiality of the
alve prosthesis in the center of the aortic annulus,
atheter-nosecone artifacts, lower profile of the
tent valve prosthesis), and future studies should
pecifically evaluate the feasibility and usefulness of
EE as the primary imaging modality in such cases.
lso, the results of this study apply only to TAVI
rocedures primarily guided by TEE with fluoros-
opy/angiography as a complementary imaging
ool. Although the results obtained in the 18
atients who underwent the procedure with no
ngiography were promising, future studies includ-
ng a larger number of patients are needed to uonfirm the safety and efficacy of TAVI fully guided
y TEE with no angiography. The relatively low
umber of patients included, especially in the
-TAVI group, might have played a role in the
bsence of differences between groups. Also,
he comparison between A-TAVI and TEE-TAVI
roups has the limitation that the A-TAVI group
epresented our initial TA-TAVI experience, and
he results in this group might have been negatively
nfluenced by the effects of the learning curve.
lthough the results obtained in the TEE-TAVI
roup are also similar to those reported in previous
A-TAVI series with angiography as a primary
maging technique, they will have to be confirmed
y studies including a larger number of patients and
imilar levels of experience in both A-TAVI and
EE-TAVI groups.
C O N C L U S I O N S
The use of TEE as the primary imaging technique
for guiding TA-TAVI was associated with clinical
and hemodynamic results similar to those of angio-
graphic TA-TAVI guidance. Also, TEE-TAVI
was associated with a significant reduction in the
use of contrast media during the procedures, and
this might have major clinical implications with
respect to the occurrence of post-procedural con-
trast nephropathy. Finally, although an operating
room with hybrid facilities is the optimal scenario
to perform TA-TAVI procedures, our results
suggest the feasibility and safety of performing
TA-TAVI procedures in a regular operating
room without hybrid facilities. The confirmation
of these findings in future studies might have
important logistic and financial implications in
the near future when a very rapid expansion of
TAVI procedures worldwide is expected and
many new centers, most of them with no hybrid
operating rooms, will want to start a TA-TAVI
program.
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